$2.28
0.89%
Nasdaq, Jul 03, 07:00 pm CET
ISIN
US00773U1088
Symbol
ADVM
Sector
Industry

Adverum Biotechnologies Inc Stock price

$2.28
-0.23 9.16% 1M
-2.73 54.49% 6M
-2.39 51.18% YTD
-4.85 68.02% 1Y
-9.52 80.68% 3Y
-205.92 98.90% 5Y
-158.02 98.58% 10Y
-277.62 99.19% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
+0.02 0.89%
ISIN
US00773U1088
Symbol
ADVM
Sector
Industry

Key metrics

Basic
Market capitalization
$47.6m
Enterprise Value
$-35.5m
Net debt
positive
Cash
$83.1m
Shares outstanding
20.8m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 245.8
EV/Sales
- | negative
EV/FCF
0.3
P/B
1.8
Financial Health
Equity Ratio
39.3%
Return on Equity
-185.2%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $193.8k
EBITDA
- | $-182.6m
EBIT
- | $-179.8m
Net Income
- | $-120.7m
Free Cash Flow
$-112.5m
Growth (TTM | estimate)
Revenue
- | -80.6%
EBITDA
- | -34.7%
EBIT
-
Net Income
- | 7.8%
Free Cash Flow
-21.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -94,210.5%
EBIT
-
Net
- | -62,301.9%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-5.4
Short interest
10.1%
Employees
155
Rev per Employee
$10.0k
Show more

Is Adverum Biotechnologies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Adverum Biotechnologies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Adverum Biotechnologies Inc forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Adverum Biotechnologies Inc forecast:

Buy
82%
Hold
18%

Financial data from Adverum Biotechnologies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1 1
72% 72%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
22% 22%
6,076%
- Research and Development Expense 77 77
1% 1%
7,704%
-133 -133
13% 13%
-13,315%
- Depreciation and Amortization 3.65 3.65
35% 35%
365%
EBIT (Operating Income) EBIT -137 -137
11% 11%
-13,680%
Net Profit -129 -129
10% 10%
-12,857%

In millions USD.

Don't miss a Thing! We will send you all news about Adverum Biotechnologies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adverum Biotechnologies Inc Stock News

Neutral
GlobeNewsWire
about one month ago
REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum's 201...
Neutral
GlobeNewsWire
about 2 months ago
-   Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD -  Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3.5 years after Ixo-vec administration, establishing the potential for life-long vision preservation REDWOOD CITY, Calif., May 14, 2025 (GLOB...
Neutral
GlobeNewsWire
2 months ago
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's ...
More Adverum Biotechnologies Inc News

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Head office United States
CEO Laurent Fischer
Employees 155
Founded 2006
Website adverum.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today